HOLLER FRANK A 4
4 · Xenon Pharmaceuticals Inc. · Filed Sep 13, 2019
Insider Transaction Report
Form 4
HOLLER FRANK A
Director
Transactions
- Tax Payment
Common Shares
2019-09-12$9.38/sh−934$8,761→ 123,259 total - Exercise/Conversion
Common Shares
2019-09-12$3.00/sh+25,720$77,160→ 148,979 total - Tax Payment
Common Shares
2019-09-12$9.38/sh−7,781$72,986→ 141,198 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-09-12−3,086→ 0 totalExercise: $3.70Exp: 2019-09-18→ Common Shares (3,086 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2019-09-12−3,086→ 0 totalExercise: $3.07Exp: 2019-09-18→ Common Shares (3,086 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2019-09-12−25,720→ 0 totalExercise: $3.00Exp: 2019-09-18→ Common Shares (25,720 underlying) - Exercise/Conversion
Common Shares
2019-09-12$3.70/sh+3,086$11,418→ 122,041 total - Tax Payment
Common Shares
2019-09-12$9.38/sh−934$8,761→ 121,107 total - Exercise/Conversion
Common Shares
2019-09-12$3.07/sh+3,086$9,474→ 124,193 total
Footnotes (5)
- [F1]The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- [F2]Represents the closing price of the Company's common shares on September 11, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- [F3]The shares subject to the option fully vested on May 31, 2011. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.
- [F4]The shares subject to the option fully vested on December 31, 2011. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.
- [F5]The shares subject to the option fully vested February 1, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.